Clinical Affairs Excellence: Benchmarking Clinical Budgets and Staffing for Pharmaceutical Success in a Global Marketplace

STUDY OVERVIEW

Clinical programs at biopharmaceutical organizations are increasingly looking to less expensive and regulated areas of the world to perform clinical trial activities. Emerging markets are also fast-growing regions that present future growth opportunities for organizations that have seen sales growth slow in mature markets.

However, there are still questions around the cost, quality and pitfalls of conducting clinical trials in emerging regions.

Best Practices®, LLC conducted this study to inform clinical affairs leaders at biopharma companies on benchmarks around budgets, and staffing. In addition, the study presents benchmarks and insights around the current level of clinical trials in emerging areas, the cost and quality of outside-U.S. trials, and outsourcing levels for key clinical activities.

Critical outsourcing questions addressed in this survey include:

• What are the regions where biopharmaceutical companies are conducting clinical trials and the percent of patients recruited annually from these regions?
• Which clinical trial activities are best suited for outsourcing?
• What is the appropriate staffing mix (in-house and outsourced) for clinical trials?

• Outside-U.S. Clinical Trial Overview and Insights
• Clinical Affairs Budget and FTEs
• Clinical Affairs Presence Around the World
• Cost and Quality of Outside-U.S. Trials and Outsourcing
• Outsourcing Levels for Key Clinical Activities
  

• Company revenues and clinical affairs spend
• Percentage of Clinical Affairs budget dedicated for studies
• Number of FTEs in global clinical affairs organization and FTEs per $100M in revenue
• Percentage of Clinical Affairs staffing working in emerging markets (BRIC)
• Percentage mix of Clinical Affairs staffing in terms of in-house, outsourced and offshored
• Optimal mix of U.S. and outside-U.S. trial sites/volunteers to meet FDA quality standards
• Regions where conducting clinical trials and percentage of patients from each region
• Experience with cost of outside U.S. trials
• Regulatory authorities reaction to clinical data from outside-U.S. trials
• Level of satisfaction with quality of outside-U.S. trials
• Percentage of outsourcing and in-house staff used for seven key clinical activities
• Rating of outsourcing suitability for seven key clinical activities
  

• Pharma participants believe even strongly (86 percent) that trial activity in emerging markets will increase in the coming years. Likewise, a majority of pharma participants believe both offshore and outsourced staffing will increase as well.
  
• The pharma segment indicated that they outsourced a majority of all seven of the key clinical activities benchmarked in this study.

Research participants included 7 executives and managers from 6 pharmaceuticalcompanies across a wide variety of therapeutic areas and product classes. In addition, four in-depth interviews were conducted to capture innovative practices in clinical activities in emerging areas.

Industries Profiled:
Health Care; Pharmaceutical; Biotech; Medical Device


Companies Profiled:
Eisai; Abbott Laboratories; Daiichi Sankyo; CSL Behring; Roche; MerckSerono

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.